search icon
Join IDSAJOIN IDSA >> Go to MyIDSAGO TO MYIDSA >>
  • Print
  • ShareThis
  • Text Size

IDSA Practice Guidelines

Practice guidelines are systematically developed statements to assist practitioners and patients in making decisions about appropriate health care for specific clinical circumstances. [Institute of Medicine Committee to Advise the Public Health Service on Clinical Practice Guidelines, 1990]

Attributes of good guidelines include validity, reliability, reproducibility, clinical applicability, clinical flexibility, clarity, multidisciplinary process, review of evidence, and documentation. [Institute of Medicine Committee to Advise the Public Health Service on Clinical Practice Guidelines, 1990]

Keyword Search

...

Search Results

3 results found

Blastomycosis

Status: Current

Blastomycosis refers to disease caused by the dimorphic fungusBlastomyces dermatitidis.This infection occurs most often in persons living in midwestern, southeastern, and south central United States and the Canadian provinces that

Blastomycosis refers to disease caused by the dimorphic fungusBlastomyces dermatitidis.This infection occurs most often in persons living in midwestern, southeastern, and south central United States and the Canadian provinces that border the Great Lakes and the St. Lawrence Seaway. Recent reports have shown an increase in the incidence of blastomycosis in some of these regions. Full text*Every 12 to 18 months following publication, IDSA reviews its guidelines to determine whether an update is required. This guideline was last reviewed and deemed current as of 04/2013.

Sporotrichosis

Status: Current

Guidelines for the management of patients with sporotrichosis were prepared by an Expert Panel of the Infectious Diseases Society of America and replace the guidelines published in 2000... They include

Guidelines for the management of patients with sporotrichosis were prepared by an Expert Panel of the Infectious Diseases Society of America and replace the guidelines published in 2000... They include evidence-based recommendations for the management of patients with lymphocutaneous, cutaneous, pulmonary, osteoarticular, meningeal, and disseminated sporotrichosis. Recommendations are also provided for the treatment of sporotrichosis in pregnant women and in children.*Every 12 to 18 months following publication, IDSA reviews its guidelines to determine whether an update is required. This guideline was last reviewed and deemed current as of 04/2013

Histoplasmosis

Status: Current

Every 12 to 18 months following publication, IDSA reviews its guidelines to determine whether an update is required. This guideline was last reviewed and deemed current as of 06/2011.These updated

Every 12 to 18 months following publication, IDSA reviews its guidelines to determine whether an update is required. This guideline was last reviewed and deemed current as of 06/2011.These updated guidelines replace the previous treatment guidelines published in 2000. The guidelines are intended for use by health care providers who care for patients who either have these infections or may be at risk for them. Since 2000, several new antifungal agents have become available, and clinical trials and case series have increased our understanding of the management of histoplasmosis. Advances in immunosuppressive treatment for inflammatory disorders have created new questions about the approach to prevention and treatment of histoplasmosis.  Full text

| HIVMA | Contact Us

© Copyright IDSA 2018 Infectious Diseases Society of America

Full Site Mobile Site